Howe & Rusling Inc. Purchases Shares of 53,182 Astrazeneca Plc $AZN

Howe & Rusling Inc. purchased a new position in Astrazeneca Plc (NYSE:AZN) in the 1st quarter, HoldingsChannel reports. The fund purchased 53,182 shares of the company’s stock, valued at approximately $10,488,000.

A number of other large investors have also modified their holdings of the stock. MV Capital Management Inc. purchased a new position in Astrazeneca in the fourth quarter valued at $26,000. Reflection Asset Management purchased a new stake in Astrazeneca during the 4th quarter worth about $31,000. Lloyd Advisory Services LLC. purchased a new stake in Astrazeneca during the 4th quarter worth about $35,000. Basepoint Wealth LLC acquired a new stake in Astrazeneca in the 4th quarter valued at about $44,000. Finally, Acumen Wealth Advisors LLC acquired a new stake in Astrazeneca in the 4th quarter valued at about $47,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of analyst reports. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Performance

Shares of AZN opened at $194.96 on Friday. The stock has a 50 day moving average price of $183.96 and a 200 day moving average price of $188.09. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $302.36 billion, a price-to-earnings ratio of 29.27, a price-to-earnings-growth ratio of 1.58 and a beta of 0.24. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts predict that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.